Dishman Carbogen Amcis Ltd vs Venus Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Dishman Carbogen Amcis Ltd is ₹ 189.15 as of 06 May 15:30 . The P/E Ratio of Dishman Carbogen Amcis Ltd changed from 161 on March 2022 to 1036 on March 2025 . This represents a CAGR of 59.28% over 4 yearsThe P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2021 to 8.8 on March 2025 . This represents a CAGR of 9.86% over 5 years The Market Cap of Dishman Carbogen Amcis Ltd changed from ₹ 1708 crore on March 2021 to ₹ 3411 crore on March 2025 . This represents a CAGR of 14.83% over 5 yearsThe Market Cap of Venus Remedies Ltd changed from ₹ 338.91 crore on March 2021 to ₹ 400.47 crore on March 2025 . This represents a CAGR of 3.39% over 5 years The revenue of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 726.46 crore as compare to the Sep '25 revenue of ₹ 660.76 crore. This represent the growth of 9.94% The revenue of Venus Remedies Ltd for the Dec '25 is ₹ 182.78 crore as compare to the Sep '25 revenue of ₹ 194.46 crore. This represent the decline of -6.01% The ebitda of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 119.77 crore as compare to the Sep '25 ebitda of ₹ 157 crore. This represent the decline of -23.71% The ebitda of Venus Remedies Ltd for the Dec '25 is ₹ 40.04 crore as compare to the Sep '25 ebitda of ₹ 32.67 crore. This represent the growth of 22.56% The net profit of Dishman Carbogen Amcis Ltd changed from ₹ -77.57 crore to ₹ -12.97 crore over 7 quarters. This represents a CAGR of -64.01% The net profit of Venus Remedies Ltd changed from ₹ 1.22 crore to ₹ 25.58 crore over 7 quarters. This represents a CAGR of 469.07% The Dividend Payout of Dishman Carbogen Amcis Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Limited was formerly incorporated as 'Carbogen Amcis (India) Limited' on July 17, 2007.
The Company name later on, was changed to 'Dishman Carbogen Amcis Limited' on 27 March 2017.
The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants.
It works manufacturing and research facilities in India, Switzerland, France, The Netherland and China. During the financial year ended 31 March 2017, Dishman Pharmaceuticals and Chemicals Limited (DPCL) and Dishman Care Limited were merged with DPCL's subsidiary Carbogen Amcis (India) Limited, with the key objective of business consolidation and simplification of the Group structure.
The name of Carbogen Amcis (India) Ltd.

About Venus Remedies Ltd

Incorporated in 1989 Venus Remedies Limited, formerly known as Venus Glucose Pvt Ltd, was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
The Company was promoted and managed by Chaudhary & Family.
The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). At present, Venus focuses on specialized therapeutic areas including anti-infectives (antibiotics), oncology, neurology, pain management, and skin and wound care.
In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

FAQs for the comparison of Dishman Carbogen Amcis Ltd and Venus Remedies Ltd

Which company has a larger market capitalization, Dishman Carbogen Amcis Ltd or Venus Remedies Ltd?

Market cap of Dishman Carbogen Amcis Ltd is 2,965 Cr while Market cap of Venus Remedies Ltd is 1,235 Cr

What are the key factors driving the stock performance of Dishman Carbogen Amcis Ltd and Venus Remedies Ltd?

The stock performance of Dishman Carbogen Amcis Ltd and Venus Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dishman Carbogen Amcis Ltd and Venus Remedies Ltd?

As of May 6, 2026, the Dishman Carbogen Amcis Ltd stock price is INR ₹189.15. On the other hand, Venus Remedies Ltd stock price is INR ₹924.5.

How do dividend payouts of Dishman Carbogen Amcis Ltd and Venus Remedies Ltd compare?

To compare the dividend payouts of Dishman Carbogen Amcis Ltd and Venus Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.